

PRESS RELEASE

Lyon, January 25, 2024



ADOCIA Announces its Financial Calendar for 2024

6:00 pm CET- Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today its financial calendar for 2024.

February 27, 2024	Publication of revenue Q4 2023
April 24, 2024	Publication of 2023 financial statements
May 14, 2024	Publication of revenue for Q1 2024
July 24, 2024	Publication of revenue for Q2 2024
September 19, 2024	Publication of mid-year financial statements as of June 30, 2024
October 30, 2024	Publication of revenue for Q3 2024

In addition to regular meetings with the financial community, investors can also find updated information on the company's website (www.adocia.com).

All corporate information on the company such as its financial statements, its corporate presentation and its status is available on the company's website, in the Investors' section "[Regulated Information](#)".

About Adocia

[Adocia](#) is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.

The company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining insulins with other classes of hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with a first application in pancreatic cells transplantation; 4) AdoGel®, a long-acting drug delivery platform.

Adocia holds more than 25 patent families.

Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).

Contact

Adocia

Olivier Soula

CEO

www.adocia.com

contactinvestisseurs@adocia.com

+33 4 72 610 610

Ulysse Communication

Adocia Press and Investors Relations

Pierre-Louis Germain

Bruno Arabian

adocia@ulyse-communication.com

+ 33 (0)6 64 79 97 51



European **Rising Tech**
LABEL



ADOCIA

innovative medicine
for everyone, everywhere



Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the universal registration document that was filed with the French Autorité des marchés financiers on April 26, 2023 updated by the amendment of 26 July 2023 (D.23-0346-A01) and amendment of 13 September 2023 (D.23-0346-A02), available at www.adocia.com,

in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.

The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.